← Ascendis Pharma A/S
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $4.6m |
$1.5m
-66.78%
|
$10.6m
+591.57%
|
$13.4m
+26.41%
|
$7.0m
-48.01%
|
$7.8m
+11.87%
|
$51.2m
+557.93%
|
$266.7m
+421.20%
|
$363.6m
+36.34%
|
$720.1m
+98.03%
|
$865.8m
+20.23%
|
|
| Revenue From Interest | $123k | $923k | $4.0m | $10.1m | $1.8m | $692k | $7.4m | $16.9m | $14.4m | $15.3m | — | |
| Cost of Goods and Services Sold | — | — | — | $0 | $0 | $3.5m |
$12.1m
+244.51%
|
$44.4m
+265.78%
|
$44.3m
-0.31%
|
$94.9m
+114.46%
|
$94.9m
-0.00%
|
|
| Gross Profit | — | — | — | $13.4m |
$7.0m
-48.01%
|
$4.3m
-38.80%
|
$39.0m
+817.44%
|
$222.3m
+469.52%
|
$319.4m
+43.66%
|
$625.2m
+95.76%
|
$770.9m
+23.30%
|
|
| Research and development | $66.0m | $99.6m | $140.3m | $191.6m | $260.9m | $295.9m | $379.6m | $413.5m | $307.0m | $303.6m | $276.1m | |
| Selling, General and Administrative Expense | $11.5m | $13.5m | $25.1m | $48.5m | $76.7m | $160.2m | $221.2m | $264.4m | $291.1m | $457.9m | $492.2m | |
| Operating expenses: | ||||||||||||
| Interest Expense | $5k | $97k | $127k | $207k | $1.9m | $3.9m | $30.7m | $44.1m | $65.5m | $80.6m | $103.1m | |
| Interest Expense On Lease Liabilities | — | — | — | $1.0m | $1.6m | $3.4m | $3.8m | $3.6m | $3.3m | $4.2m | $103.1m | |
| Current Tax Expense (Income) | ($227k) | ($477k) | $394k | $234k | $219k | $367k | ($5.4m) | ($5.4m) | ($3.3m) | ($12.6m) | — | |
| Deferred Tax Expense (Income) | — | — | ($3.1m) | — | — | — | — | — | — | — | — | |
| Deferred Tax Expense (Income) Recognised In Profit Or Loss | — | — | — | — | — | — | — | — | — | ($3.3m) | — | |
| Income Tax Expense Continuing Operations | ($227k) | ($477k) | ($394k) | ($234k) | ($219k) | ($367k) | $5.4m | $7.3m | $4.8m | $15.4m | ($663.2m) | |
| Basic Earnings (Loss) Per Share | ($2.58) | ($3.68) | ($3.17) | ($4.69) | ($8.28) | ($7.00) | ($10.40) | ($8.55) | ($6.53) | ($3.76) | $8.02 | |
| Diluted Earnings (Loss) Per Share | ($2.58) | ($3.68) | ($3.17) | ($4.69) | ($8.28) | ($7.00) | ($10.40) | ($8.55) | ($6.53) | ($3.76) | $7.57 | |
| Additional Financial Items | ||||||||||||
| Applicable Tax Rate | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — | |
| Auditors Remuneration For Tax Services | ($68.7m) | ($124.4m) | ($130.5m) | ($218.2m) | $104k | $87k | $138k | $122k | $91k | $0 | — | |
| Average Effective Tax Rate | — | — | ($0) | ($0) | ($0) | ($0) | ($0) | $0 | $0 | $0 | — | |
| Depreciation Right of Use Assets | — | — | — | — | — | $11.0m | $11.7m | $11.9m | $12.3m | $12.3m | $9.8m | |
| Employee Benefits Expense | $23.6m | $31.1m | $51.3m | $90.9m | $136.8m | $178.4m | $214.7m | $258.5m | $292.5m | $376.6m | — | |
| Expense From Share-Based Payment Transactions With Employees | $7.3m | $9.7m | $19.7m | $37.5m | $53.2m | $66.8m | $64.2m | $66.7m | $95.5m | $116.2m | — | |
| Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used | — | — | — | $202k | $470k | $186k | $280k | $353k | $285k | ($228.0m) | — | |
| Finance Costs | $3.1m | $13.8m | $127k | $1.2m | $80.8m | $3.9m | $50.5m | $44.1m | $100.0m | $206.7m | — | |
| Finance Income | $7.3m | $923k | $24.7m | $17.8m | $1.8m | $59.7m | $52.2m | $43.9m | $25.6m | $114.0m | — | |
| Impairment Loss Recognised In Profit Or Loss Goodwill | $0 | $0 | $0 | $0 | — | — | — | — | — | — | — | |
| Other Employee Expense | — | — | — | — | — | — | — | $4.2m | $4.1m | $5.2m | — | |
| Other Finance Cost | — | — | — | — | — | — | $4.3m | — | — | — | — | |
| Postemployment Benefit Expense Defined Benefit Plans | $49k | $324k | $444k | $648k | $943k | $2.4m | $4.2m | $4.4m | $4.5m | $6.9m | — | |
| Profit Loss Attributable To Owners Of Parent | ($68.7m) | ($124.4m) | ($130.5m) | ($218.2m) | ($419.0m) | ($383.6m) | ($583.2m) | ($481.4m) | ($378.1m) | ($228.0m) | — | |
| Profit Loss Before Tax | ($68.7m) | ($124.4m) | ($130.5m) | ($218.2m) | ($419.2m) | ($383.9m) | ($577.8m) | ($474.1m) | ($373.2m) | ($212.7m) | — | |
| Profit Loss From Operating Activities | ($72.9m) | ($111.5m) | ($154.8m) | ($226.7m) | ($330.6m) | ($451.8m) | ($561.8m) | ($455.5m) | ($278.8m) | ($136.3m) | — | |
| Net Foreign Exchange Loss | $3.1m | $13.7m | — | — | $78.9m | — | — | — | $27.1m | $0 | — |